Alumis posts corporate presentation update; no material new data disclosed in filing

ALUMIS INC.

Filed a June 2026 corporate deck under Item 8.01 for investor meetings.
Exhibit 99.1 only contains a title slide; no clinical, financial, or pipeline specifics provided.
No guidance changes, trial results, or operational milestones mentioned in the filing.
Company ticker ALMS trades on Nasdaq; emerging growth company status reaffirmed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.